Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CASR | P41180 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL547466 | 1.00 | PGR (0.49) | PGRKMT2AMEN1SMN1; SMN2GFER | |
| SCHEMBL4961089 | 1.00 | PGR (0.49) | PGRKMT2AMEN1SMN1; SMN2GFER | |
| SCHEMBL10712658 | 0.83 | CYP19A1 (0.45) | PGRKMT2ASMN1; SMN2GFERCYP3A4 | |
| SCHEMBL3253398 | 0.82 | PGR (0.48) | PGRKMT2AMEN1SMN1; SMN2GFER | |
| SCHEMBL11370625 | 0.81 | HSP90AA1 (0.50) | KMT2AMEN1SMN1; SMN2CYP3A4ALDH1A1 | |
| SCHEMBL10083640 | 0.81 | MEN1 (0.47) | PGRKMT2AMEN1SMN1; SMN2CYP3A4 | |
| SCHEMBL30606438 | 0.80 | KMT2A (0.46) | KMT2AMEN1CYP3A4ALDH1A1ALOX15 | |
| SCHEMBL3984867 | 0.80 | MAPT (0.42) | PGRKMT2ASMN1; SMN2CYP3A4ALDH1A1 | |
| SCHEMBL11622213 | 0.80 | PGR (0.42) | PGRKMT2AMEN1SMN1; SMN2GFER | |
| SCHEMBL18095020 | 0.80 | PGR (0.42) | PGRKMT2AMEN1SMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110569-B2 | Enantiomerically pure S-etifoxine, pharmaceutical compositions thereof and methods of their use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110569-B2 | Enantiomerically pure S-etifoxine, pharmaceutical compositions thereof and methods of their use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110569-B2 | Enantiomerically pure S-etifoxine, pharmaceutical compositions thereof and methods of their use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-07 | — | — | US | disclosed |
| US-20080038331-A1 | Enantiomerically pure S-etifoxine, pharmaceutical compositions thereof and methods of their use | ANVYL LLC | 2008-02-14 | — | — | US | disclosed |
| US-20080038331-A1 | Enantiomerically pure S-etifoxine, pharmaceutical compositions thereof and methods of their use | ANVYL LLC | 2008-02-14 | — | — | US | disclosed |
| US-20080038331-A1 | Enantiomerically pure S-etifoxine, pharmaceutical compositions thereof and methods of their use | ANVYL LLC | 2008-02-14 | — | — | US | disclosed |
| US-20080039453-A1 | Enantiomerically pure R-etifoxine, pharmaceutical compositions thereof and methods of their use | OXFORD FINANCE CORPORATION | 2008-02-14 | — | — | US | disclosed |
| US-20080039453-A1 | Enantiomerically pure R-etifoxine, pharmaceutical compositions thereof and methods of their use | OXFORD FINANCE CORPORATION | 2008-02-14 | — | — | US | disclosed |
| WO-2007109288-A2 | ENANTIOMERICALLY PURE R-ETIFOXINE, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS OF THEIR USE | XYTIS INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007109289-A1 | ENANTIOMERICALLY PURE S-ETIFOXINE, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS OF THEIR USE | XYTIS INC. (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080038331-A1 | Enantiomerically pure S-etifoxine, pharmaceutical compositions thereof and methods of their use | PYGB, CYP2C9, CYP3A5 | PGR 1587/4885KMT2A 1976/4885MEN1 1960/4885 |
| US-20080039453-A1 | Enantiomerically pure R-etifoxine, pharmaceutical compositions thereof and methods of their use | PYGB, GRIK5, CYP3A5 | PGR 633/4885KMT2A 1795/4885MEN1 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.